查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1470686

晝夜節律睡眠治療市場：依地區（北美、歐洲、亞太地區、拉丁美洲、中東非洲）：全球產業分析、規模、佔有率、成長、趨勢、預測，2024-2031年

Circadian Rhythm Sleep Treatment Market by Geography (North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa): Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2024-2031
出版日期: | 出版商: Persistence Market Research | 英文 310 Pages | 商品交期: 2-5個工作天內

價格
簡介目錄

由於人們對睡眠障礙的認識不斷提高以及睡眠醫學的進步，晝夜節律睡眠治療市場是一個快速發展的領域。 這個市場包括各種旨在解決影響睡眠-覺醒週期和整體健康的體內生理時鐘紊亂的治療方法和治療方法。 本報告深入探討了 2024 年至 2031 年晝夜節律睡眠治療市場的成長動力、潛在課題和新興趨勢，為利害關係人和醫療保健專業人士提供了寶貴的見解。

預計全球晝夜節律睡眠治療市場將在預測期內穩定成長，2024年至2031年的複合年增長率為4.7%。 該市場預計將從 2024 年的 7.84 億美元成長到 2031 年底的 11 億美元。

關鍵見解

  • 預計市場價值（2024 年）：7.84 億美元
  • 預計市值（2031 年）：11 億美元
  • 全球市場成長率（2024-2031 年複合年增長率）：4.7%

晝夜節律睡眠治療市場 - 報告範圍：

晝夜節律睡眠障礙 (CRSD) 會影響自然的睡眠-覺醒週期，並且由於現代生活方式的改變和人造光暴露的增加而變得越來越常見。 這些疾病包括睡眠時相延遲障礙 (DSPD)、睡眠時相提前障礙 (ASPD)、輪班工作障礙和時差障礙。 本報告探討了可用的治療方法，包括光療、褪黑激素補充劑、行為治療和藥理學方法。

市場驅動因素：

晝夜節律睡眠治療市場的成長受到多種因素的推動。 提高人們對睡眠健康重要性及其對整體健康影響的認識是一個關鍵驅動因素。 此外，由於現代生活方式、壓力和工作相關因素，睡眠障礙的盛行率日益增加，這也推動了對有效治療的需求。 睡眠技術和個人化醫療的進步正在實現更準確的診斷和量身定制的治療方法，進一步推動市場成長。 穿戴式睡眠追蹤設備和行動健康應用程式的日益普及也有助於提高對睡眠障礙的認識和管理。

市場限制因素：

儘管存在成長潛力，但晝夜節律睡眠治療市場面臨一些課題。 某些治療方法的高成本，尤其是那些涉及先進技術或個人化方法的治療方法，可能會抑制人們的吸收。 在某些地區，獲得專業睡眠診所和專家的機會有限也可能限制市場成長。 此外，一般人群缺乏對晝夜節律紊亂的認識可能會妨礙早期診斷和早期治療。 對藥物治療潛在副作用和對助眠劑的依賴的擔憂也可能影響消費者的信心。

市場機會：

晝夜節律睡眠治療市場提供了大量的創新和擴張機會。 公司可以專注於開發更容易獲得和負擔得起的治療選擇，例如光療設備和睡眠追蹤可穿戴設備。 睡眠專家和科技公司的共同努力可能會帶來更加整合和用戶友好的解決方案。 遠距醫療和虛擬諮詢的興起為擴大睡眠治療服務的覆蓋範圍提供了機會，特別是在偏遠地區。 此外，提高大眾對睡眠健康的認識活動將有助於早期診斷並鼓勵採取預防措施，最終促進市場成長。

目錄

第 1 章執行摘要

第二章市場介紹

  • 市場範圍/分類
  • 市場定義/範圍/限制

第三章全球晝夜節律睡眠治療市場的主要趨勢

  • 影響市場的主要趨勢
  • 產品創新趨勢
  • 創新與新產品
  • 區域疾病概述和流行病學（患病率數據）

第 4 章全球晝夜節律睡眠治療市場的關鍵成功因素

  • 產品採用/認知度分析
  • 產品特性與故障矩陣

第五章全球晝夜節律睡眠治療市場 - 價格分析

  • 區域價格分析
  • 價格明細
    • 製造商等級定價
    • 經銷商級定價
  • 世界平均價格分析基準

第六章全球晝夜節律睡眠治療市場需求分析與預測

  • 過去的市場價值（金額）分析，2019-2023 年
  • 2024-2031 年當前及未來市場價值（金額）預測
  • 年成長趨勢分析

第七章全球晝夜節律睡眠治療市場現況

  • 主要規定
  • 宏觀經濟因素
  • 預測因子 - 相關性和影響
  • 市場動態
    • 促進因素
    • 抑制因素
    • 機會分析

第 8 章全球晝夜節律睡眠治療市場分析及依治療類型預測

  • 簡介/主要發現
  • 過去的市場規模（金額）與數量分析，2019-2023 年
  • 2024-2031 年市場規模（金額）與數量預測
    • 設備
      • 處理設備
        • 燈箱
        • 檯燈
        • 遮光罩
        • 黎明模擬器
      • 診斷設備
        • 體動記錄感測器
        • 手腕與手帶式體動記錄儀
        • 穿戴式體動記錄儀
        • 多導睡眠監測裝置
        • 固定式多導睡眠監測裝置
        • 便攜式多導睡眠監測儀
    • 藥物
      • 苯二氮平類藥物
      • 非苯二氮平類安眠藥
      • 食慾素受體拮抗劑
      • 褪黑激素受體激動劑
    • 時間療法
  • 依治療類型進行市場吸引力分析

第 9 章全球晝夜節律睡眠治療市場依疾病分析與預測

  • 簡介/主要發現
  • 過去的市場規模（金額）分析，2019-2023 年
  • 2024-2031 年市場規模（金額）預測
    • 睡眠時相延遲症候群 (DSPS)
    • 高階睡眠階段症候群 (ASPS)
    • 非 24 小時睡眠覺醒症候群
    • 睡眠/覺醒不規律 (ISWD)
    • 輪班工作混亂
    • 時差反應
  • 依殘障狀況進行市場吸引力分析

第10章全球晝夜節律睡眠治療市場分析及通路預測

  • 簡介/主要發現
  • 過去的市場規模（金額）分析，2019-2023 年
  • 2024-2031 年市場規模（金額）預測
    • 向機構投資人銷售
      • 居家照護環境
      • 健康中心和水療中心
      • 睡眠測試中心
      • 專科診所
      • 醫院
    • 零售銷售
      • 零售藥局
      • 藥局
      • 線上銷售
  • 依分銷管道劃分的市場吸引力分析

第11章全球晝夜節律睡眠治療市場分析及地區預測

  • 簡介/主要發現
  • 過去的市場規模（金額）與數量分析，2019-2023 年
  • 2024-2031 年市場規模（金額）與數量預測
    • 北美
    • 拉丁美洲
    • 歐洲
    • 南亞
    • 東亞
    • 大洋洲
    • 中東和非洲
  • 依地區劃分的市場吸引力分析

第十二章北美晝夜節律睡眠治療市場分析與預測

第十三章拉丁美洲晝夜節律睡眠治療市場分析與預測

第14章歐洲晝夜節律睡眠治療市場分析與預測

第十五章東亞晝夜節律睡眠治療市場分析與預測

第十六章南亞晝夜節律睡眠治療市場分析與預測

第十七章大洋洲晝夜節律睡眠治療市場分析與預測

第十八章中東與非洲晝夜節律睡眠治療市場分析與預測

第19章競爭分析

  • 競爭對手儀表板
  • 有競爭力的價格分析
  • 競爭基準
  • 以競爭對手劃分的毛利分析
  • 競賽的發展
  • 衝突詳情
    • Vanda Pharmaceuticals Inc.
    • Natus Medical Incorporated
    • Compumedics Ltd.
    • Teva Pharmaceutical Industries Ltd
    • Takeda Pharmaceutical Company
    • Koninklijke Philips NV
    • Mylan NV
    • Fitbit, Inc
    • Garmin Ltd
    • Lucimed SA
    • RedMed Inc.
    • Compass Health Brands（Carex Health）
    • Beurer GmbH
    • Samarit Medical AG
    • Lanaform NV

第 20 章先決條件與使用的縮寫

第21章研究方法

簡介目錄
Product Code: PMRREP27310

The circadian rhythm sleep treatment market is a rapidly evolving sector, driven by increasing awareness about sleep disorders and advancements in sleep medicine. This market encompasses various treatments and therapies designed to address disruptions in the body's internal clock, affecting sleep-wake cycles and overall health. This report delves into the key factors driving growth, potential challenges, and emerging trends in the circadian rhythm sleep treatment market from 2024 through 2031, providing valuable insights for stakeholders and healthcare professionals.

The global circadian rhythm sleep treatment market is expected to experience steady growth during the forecast period, with a projected CAGR of 4.7% from 2024 to 2031. The market is estimated to expand from a value of USD 784 million in 2024 to USD 1.1 billion by the end of 2031.

Key Insights:

  • Estimated Market Value (2024): USD 784 million
  • Projected Market Value (2031): USD 1.1 Billion
  • Global Market Growth Rate (CAGR 2024 to 2031): 4.7%

Circadian Rhythm Sleep Treatment Market - Report Scope:

Circadian rhythm sleep disorders (CRSDs) are becoming more prevalent due to modern lifestyle changes and increased exposure to artificial light, impacting the natural sleep-wake cycle. These disorders include delayed sleep phase disorder (DSPD), advanced sleep phase disorder (ASPD), shift work disorder, and jet lag disorder. The report explores the scope of these treatments, covering various therapies such as light therapy, melatonin supplements, behavioral therapy, and pharmacological approaches.

Market Growth Drivers:

The growth of the circadian rhythm sleep treatment market is driven by several factors. Increasing awareness about the importance of sleep health and its impact on overall well-being is a significant driver. Additionally, the rising prevalence of sleep disorders due to modern lifestyles, stress, and work-related factors fuels the demand for effective treatments. Advances in sleep technology and personalized medicine are enabling more accurate diagnosis and tailored treatment approaches, further boosting market growth. The growing adoption of wearable sleep tracking devices and mobile health applications also contributes to the increased awareness and management of sleep disorders.

Market Restraints:

Despite its growth potential, the circadian rhythm sleep treatment market faces several challenges. High costs associated with some treatments, especially those involving advanced technology or personalized approaches, can deter widespread adoption. Limited access to specialized sleep clinics and professionals in certain regions may also restrict market growth. Additionally, lack of awareness about circadian rhythm disorders among the general population can hinder early diagnosis and treatment. Concerns about the potential side effects of pharmacological treatments and dependency on sleep aids can also affect consumer confidence.

Market Opportunities:

The circadian rhythm sleep treatment market presents numerous opportunities for innovation and expansion. Companies can focus on developing more accessible and affordable treatment options, such as light therapy devices and sleep-tracking wearables. Collaborative efforts between sleep experts and technology companies can lead to more integrated and user-friendly solutions. The rise of telehealth and virtual consultations offers an opportunity to expand access to sleep treatment services, especially in remote areas. Furthermore, increasing public awareness campaigns about sleep health can drive early diagnosis and encourage preventive measures, ultimately contributing to market growth.

Key Questions Addressed in the Report:

  • What is the Expected Value CAGR of the Circadian Rhythm Sleep Treatment Market?
  • What is the Revenue Size of the Global Circadian Rhythm Sleep Treatment Market as of 2024-end?
  • Which Region Held the Largest Market Share in 2024?
  • Who are the Key Players in the Global Circadian Rhythm Sleep Treatment Market?
  • What are the Most Effective Treatments for Circadian Rhythm Sleep Disorders?

Competitive Landscape and Business Strategies:

The competitive landscape in the circadian rhythm sleep treatment market features a mix of established pharmaceutical companies and innovative tech startups. Key players like Jazz Pharmaceuticals, Philips Healthcare, and Fitbit offer a range of sleep treatment solutions, from pharmacological therapies to wearable devices. Jazz Pharmaceuticals focuses on developing medications for sleep disorders, including narcolepsy and insomnia. Philips Healthcare offers a variety of sleep-related devices, such as light therapy and continuous positive airway pressure (CPAP) machines. Fitbit, a leader in wearable technology, has integrated sleep tracking features into its fitness devices, enabling users to monitor and improve their sleep patterns.

Key Companies Profiled:

  • Jazz Pharmaceuticals
  • Philips Healthcare
  • Fitbit
  • ResMed
  • Takeda Pharmaceuticals
  • Vanda Pharmaceuticals
  • Garmin
  • Zeo Health
  • Beddit
  • Casio Computer Co., Ltd.
  • Medtronic

Circadian Rhythm Sleep Treatment Market Segmentation:

By Treatment Type:

  • Light Therapy
  • Melatonin Supplements
  • Behavioral Therapy
  • Pharmacological Treatment

By Distribution Channel:

  • Hospitals and Sleep Clinics
  • Online Retail
  • Specialty Pharmacies

By Region:

  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East & Africa

Table of Contents

1. Executive Summary

  • 1.1. Global Market Outlook
  • 1.2. Demand Side Trends
  • 1.3. Supply Side Trends
  • 1.4. Disorder Roadmap Analysis
  • 1.5. Analysis and Recommendations

2. Market Introduction

  • 2.1. Market Coverage / Taxonomy
  • 2.2. Market Definition / Scope / Limitations

3. Global Circadian Rhythm Sleep Treatment Market Key Trends

  • 3.1. Key Trends Impacting the Market
  • 3.2. Product Innovation Trends
  • 3.3. Innovations & New Launches
  • 3.4. Disease Overview and Epidemiology (Prevalence Data), by Region

4. Global Circadian Rhythm Sleep Treatment Market Key Success Factors

  • 4.1. Product Adoption / Awareness Analysis
  • 4.2. Product Features Vs. Disorder Matrix

5. Global Circadian Rhythm Sleep Treatment Market - Pricing Analysis

  • 5.1. Regional Pricing Analysis
  • 5.2. Pricing Break-Up
    • 5.2.1. Manufacturer Level Pricing
    • 5.2.2. Distributor Level Pricing
  • 5.3. Global Average Pricing Analysis Benchmark

6. Global Circadian Rhythm Sleep Treatment Market Demand Analysis 2019-2023 and Forecast, 2024-2031

  • 6.1. Historical Market Value (US$ Mn) Analysis, 2019-2023
  • 6.2. Current and Future Market Value (US$ Mn) Projections, 2024-2031
  • 6.3. Y-o-Y Growth Trend Analysis

7. Global Circadian Rhythm Sleep Treatment Market Context

  • 7.1. Key Regulations
  • 7.2. Macro-Economic Factors
  • 7.3. Forecast Factors - Relevance & Impact
  • 7.4. Market Dynamics
    • 7.4.1. Drivers
    • 7.4.2. Restraints
    • 7.4.3. Opportunity Analysis

8. Global Circadian Rhythm Sleep Treatment Market Analysis 2019-2023 and Forecast 2024-2031, By Treatment Type

  • 8.1. Introduction/Key Finding
    • 8.1.1. Market Size (US$ Mn) and Volume Share Analysis By Treatment Type
    • 8.1.2. Y-o-Y Growth Analysis By Treatment Type
  • 8.2. Historical Market Size (US$ Mn) and Volume (US$ Mn) Analysis By Treatment Type, 2019-2023
  • 8.3. Market Size (US$ Mn) and Volume (US$ Mn) Forecast By Treatment Type, 2024-2031
    • 8.3.1. Devices
      • 8.3.1.1. Therapeutic Devices
        • 8.3.1.1.1. Light Box
        • 8.3.1.1.2. Desk Lamps
        • 8.3.1.1.3. Light Visor
        • 8.3.1.1.4. Dawn Simulator
      • 8.3.1.2. Diagnostic Devices
        • 8.3.1.2.1. Actigraphy Sensors
        • 8.3.1.2.1.1. Wrist and Hand band Actigraphy Devices
        • 8.3.1.2.1.2. Wearable Actigraphy Devices
        • 8.3.1.2.2. Polysomnography Devices
        • 8.3.1.2.2.1. Fixed Polysomnography Devices
        • 8.3.1.2.2.2. Portable Polysomnography Devices
    • 8.3.2. Drugs
      • 8.3.2.1. Benzodiazepines
      • 8.3.2.2. Nonbenzodiazepine hypnotics
      • 8.3.2.3. Orexin receptor antagonists
      • 8.3.2.4. Melatonin receptor agonist
    • 8.3.3. Chronotherapy
  • 8.4. Market Attractiveness Analysis By Treatment Type

9. Global Circadian Rhythm Sleep Treatment Market Analysis 2019-2023 and Forecast 2024-2031, By Disorder

  • 9.1. Introduction/Key Finding
    • 9.1.1. Market Size (US$ Mn) Analysis By Disorder
    • 9.1.2. Y-o-Y Growth Analysis By Disorder
  • 9.2. Historical Market Size (US$ Mn) Analysis By Disorder , 2019-2023
  • 9.3. Market Size (US$ Mn) Forecast By Disorder , 2024-2031
    • 9.3.1. Delayed Sleep Phase Syndrome (DSPS)
    • 9.3.2. Advanced Sleep Phase Syndrome (ASPS)
    • 9.3.3. Non-24-h Sleep-Wake Syndrome
    • 9.3.4. Irregular Sleep-Wake Disorder (ISWD)
    • 9.3.5. Shift Work Disorder
    • 9.3.6. Jet Lag
  • 9.4. Market Attractiveness Analysis By Disorder

10. Global Circadian Rhythm Sleep Treatment Market Analysis 2019-2023 and Forecast 2024-2031, By Distribution Channel

  • 10.1. Introduction/Key Finding
    • 10.1.1. Market Size (US$ Mn) Analysis By Distribution Channel
    • 10.1.2. Y-o-Y Growth Analysis By Distribution Channel
  • 10.2. Historical Market Size (US$ Mn) Analysis By Distribution Channel, 2019-2023
  • 10.3. Market Size (US$ Mn) Forecast By Distribution Channel, 2024-2031
    • 10.3.1. Institutional Sales
      • 10.3.1.1. Home Care Settings
      • 10.3.1.2. Wellness Centers & Spa
      • 10.3.1.3. Sleep Testing Centers
      • 10.3.1.4. Specialty Clinics
      • 10.3.1.5. Hospitals
    • 10.3.2. Retail Sales
      • 10.3.2.1. Retail Pharmacies
      • 10.3.2.2. Drug Stores
      • 10.3.2.3. Online Sales
  • 10.4. Market Attractiveness Analysis By Distribution Channel

11. Global Circadian Rhythm Sleep Treatment Market Analysis 2019-2023 and Forecast 2024-2031, By Region

  • 11.1. Introduction/Key Finding
    • 11.1.1. Market Size (US$ Mn) and Volume Share Analysis By Region
    • 11.1.2. Y-o-Y Growth Analysis By Region
  • 11.2. Historical Market Size (US$ Mn) and Volume (US$ Mn) Analysis By Region, 2019-2023
  • 11.3. Market Size (US$ Mn) and Volume (US$ Mn) Forecast By Region, 2024-2031
    • 11.3.1. North America
    • 11.3.2. Latin America
    • 11.3.3. Europe
    • 11.3.4. South Asia
    • 11.3.5. East Asia
    • 11.3.6. Oceania
    • 11.3.7. Middle East and Africa
  • 11.4. Market Attractiveness Analysis By Region

12. North America Circadian Rhythm Sleep Treatment Market Analysis 2019-2023 and Forecast 2024-2031

  • 12.1. Introduction
  • 12.2. Historical Market Size (US$ Mn) and Volume (US$ Mn) Analysis By Market Segments, 2019-2023
  • 12.3. Market Size (US$ Mn) and Volume (US$ Mn) Forecast By Market Segments, 2024-2031
    • 12.3.1. By Country
      • 12.3.1.1. U.S.
      • 12.3.1.2. Canada
    • 12.3.2. By Treatment Type
    • 12.3.3. By Disorder
    • 12.3.4. By Distribution Channel
  • 12.4. Market Attractiveness Analysis
    • 12.4.1. By Country
    • 12.4.2. By Treatment Type
    • 12.4.3. By Disorder
    • 12.4.4. By Distribution Channel
  • 12.5. Drivers and Restraints: Impact Analysis
  • 12.6. Key Market Participants - Intensity Mapping

13. Latin America Circadian Rhythm Sleep Treatment Market Analysis 2019-2023 and Forecast 2024-2031

  • 13.1. Introduction
  • 13.2. Historical Market Size (US$ Mn) and Volume (US$ Mn) Analysis By Market Segments, 2019-2023
  • 13.3. Market Size (US$ Mn) and Volume (US$ Mn) Forecast By Market Segments, 2024-2031
    • 13.3.1. By Country
      • 13.3.1.1. Brazil
      • 13.3.1.2. Mexico
      • 13.3.1.3. Argentina
      • 13.3.1.4. Rest of Latin America
    • 13.3.2. By Treatment Type
    • 13.3.3. By Disorder
    • 13.3.4. By Distribution Channel
  • 13.4. Market Attractiveness Analysis
    • 13.4.1. By Country
    • 13.4.2. By Treatment Type
    • 13.4.3. By Disorder
    • 13.4.4. By Distribution Channel
  • 13.5. Drivers and Restraints: Impact Analysis
  • 13.6. Key Market Participants - Intensity Mapping

14. Europe Circadian Rhythm Sleep Treatment Market Analysis 2019-2023 and Forecast 2024-2031

  • 14.1. Introduction
  • 14.2. Historical Market Size (US$ Mn) and Volume (US$ Mn) Analysis By Market Segments, 2019-2023
  • 14.3. Market Size (US$ Mn) and Volume (US$ Mn) Forecast By Market Segments, 2024-2031
    • 14.3.1. By Country
      • 14.3.1.1. U.K.
      • 14.3.1.2. Germany
      • 14.3.1.3. France
      • 14.3.1.4. Italy
      • 14.3.1.5. Spain
      • 14.3.1.6. BENELUX
      • 14.3.1.7. Nordic
      • 14.3.1.8. Poland
      • 14.3.1.9. Rest of Europe
    • 14.3.2. By Treatment Type
    • 14.3.3. By Disorder
    • 14.3.4. By Distribution Channel
  • 14.4. Market Attractiveness Analysis
    • 14.4.1. By Country
    • 14.4.2. By Treatment Type
    • 14.4.3. By Disorder
    • 14.4.4. By Distribution Channel
  • 14.5. Drivers and Restraints: Impact Analysis
  • 14.6. Key Market Participants - Intensity Mapping

15. East-Asia Circadian Rhythm Sleep Treatment Market Analysis 2019-2023 and Forecast 2024-2031

  • 15.1. Introduction
  • 15.2. Historical Market Size (US$ Mn) and Volume (US$ Mn) Analysis By Market Segments, 2019-2023
  • 15.3. Market Size (US$ Mn) and Volume (US$ Mn) Forecast By Market Segments, 2024-2031
    • 15.3.1. By Country
      • 15.3.1.1. China
      • 15.3.1.2. Japan
      • 15.3.1.3. South Korea
      • 15.3.1.4. Rest of East Asia
    • 15.3.2. By Treatment Type
    • 15.3.3. By Disorder
    • 15.3.4. By Distribution Channel
  • 15.4. Market Attractiveness Analysis
    • 15.4.1. By Country
    • 15.4.2. By Treatment Type
    • 15.4.3. By Disorder
    • 15.4.4. By Distribution Channel
  • 15.5. Drivers and Restraints: Impact Analysis
  • 15.6. Key Market Participants - Intensity Mapping

16. South Asia Circadian Rhythm Sleep Treatment Market Analysis and Forecast 2019-2023 and Forecast 2024-2031

  • 16.1. Introduction
  • 16.2. Historical Market Size (US$ Mn) and Volume (US$ Mn) Analysis By Market Segments, 2019-2023
  • 16.3. Market Size (US$ Mn) and Volume (US$ Mn) Forecast By Market Segments, 2024-2031
    • 16.3.1. By Country
      • 16.3.1.1. India
      • 16.3.1.2. Thailand
      • 16.3.1.3. Malaysia
      • 16.3.1.4. Indonesia
      • 16.3.1.5. Philippines
      • 16.3.1.6. Rest of South Asia
    • 16.3.2. By Treatment Type
    • 16.3.3. By Disorder
    • 16.3.4. By Distribution Channel
  • 16.4. Market Attractiveness Analysis
    • 16.4.1. By Country
    • 16.4.2. By Treatment Type
    • 16.4.3. By Disorder
    • 16.4.4. By Distribution Channel
  • 16.5. Drivers and Restraints: Impact Analysis
  • 16.6. Key Market Participants - Intensity Mapping

17. Oceania Circadian Rhythm Sleep Treatment Market Analysis and Forecast 2019-2023 and Forecast 2024-2031

  • 17.1. Introduction
  • 17.2. Historical Market Size (US$ Mn) and Volume (US$ Mn) Analysis By Market Segments, 2019-2023
  • 17.3. Market Size (US$ Mn) and Volume (US$ Mn) Forecast By Market Segments, 2024-2031
    • 17.3.1. By Country
      • 17.3.1.1. Australia
      • 17.3.1.2. New Zealand
    • 17.3.2. By Treatment Type
    • 17.3.3. By Disorder
    • 17.3.4. By Distribution Channel
  • 17.4. Market Attractiveness Analysis
    • 17.4.1. By Country
    • 17.4.2. By Treatment Type
    • 17.4.3. By Disorder
    • 17.4.4. By Distribution Channel
  • 17.5. Drivers and Restraints: Impact Analysis
  • 17.6. Key Market Participants - Intensity Mapping

18. MEA Circadian Rhythm Sleep Treatment Market Analysis and Forecast 2019-2023 and Forecast 2024-2031

  • 18.1. Introduction
  • 18.2. Historical Market Size (US$ Mn) and Volume (US$ Mn) Analysis By Market Segments, 2019-2023
  • 18.3. Market Size (US$ Mn) and Volume (US$ Mn) Forecast By Market Segments, 2024-2031
    • 18.3.1. By Country
      • 18.3.1.1. GCC Countries
      • 18.3.1.2. Iran
      • 18.3.1.3. Israel
      • 18.3.1.4. Turkey
      • 18.3.1.5. Rest of MEA
    • 18.3.2. By Treatment Type
    • 18.3.3. By Disorder
    • 18.3.4. By Distribution Channel
  • 18.4. Market Attractiveness Analysis
    • 18.4.1. By Country
    • 18.4.2. By Treatment Type
    • 18.4.3. By Disorder
    • 18.4.4. By Distribution Channel
  • 18.5. Drivers and Restraints: Impact Analysis
  • 18.6. Key Market Participants - Intensity Mapping

19. Competition Analysis

  • 19.1. Competition Dashboard
  • 19.2. Pricing Analysis, By Competition
  • 19.3. Competition Benchmarking
  • 19.4. Gross Margin Analysis, By Competition
  • 19.5. Competition Developments
  • 19.6. Competition Deep Dive
    • 19.6.1. Vanda Pharmaceuticals Inc.
      • 19.6.1.1. Overview
      • 19.6.1.2. Product and Disorder Portfolio
      • 19.6.1.3. Production Footprint
      • 19.6.1.4. Sales Footprint
      • 19.6.1.5. Strategy
        • 19.6.1.5.1. Marketing Strategy
        • 19.6.1.5.2. Product Strategy
        • 19.6.1.5.3. Channel Strategy
    • 19.6.2. Natus Medical Incorporated
      • 19.6.2.1. Overview
      • 19.6.2.2. Product and Disorder Portfolio
      • 19.6.2.3. Production Footprint
      • 19.6.2.4. Sales Footprint
      • 19.6.2.5. Strategy
        • 19.6.2.5.1. Marketing Strategy
        • 19.6.2.5.2. Product Strategy
        • 19.6.2.5.3. Channel Strategy
    • 19.6.3. Compumedics Ltd.
      • 19.6.3.1. Overview
      • 19.6.3.2. Product and Disorder Portfolio
      • 19.6.3.3. Production Footprint
      • 19.6.3.4. Sales Footprint
      • 19.6.3.5. Strategy
        • 19.6.3.5.1. Marketing Strategy
        • 19.6.3.5.2. Product Strategy
        • 19.6.3.5.3. Channel Strategy
    • 19.6.4. Teva Pharmaceutical Industries Ltd
      • 19.6.4.1. Overview
      • 19.6.4.2. Product and Disorder Portfolio
      • 19.6.4.3. Production Footprint
      • 19.6.4.4. Sales Footprint
      • 19.6.4.5. Strategy
        • 19.6.4.5.1. Marketing Strategy
        • 19.6.4.5.2. Product Strategy
        • 19.6.4.5.3. Channel Strategy
    • 19.6.5. Takeda Pharmaceutical Company
      • 19.6.5.1. Overview
      • 19.6.5.2. Product and Disorder Portfolio
      • 19.6.5.3. Production Footprint
      • 19.6.5.4. Sales Footprint
      • 19.6.5.5. Strategy
        • 19.6.5.5.1. Marketing Strategy
        • 19.6.5.5.2. Product Strategy
        • 19.6.5.5.3. Channel Strategy
    • 19.6.6. Koninklijke Philips N.V
      • 19.6.6.1. Overview
      • 19.6.6.2. Product and Disorder Portfolio
      • 19.6.6.3. Production Footprint
      • 19.6.6.4. Sales Footprint
      • 19.6.6.5. Strategy
        • 19.6.6.5.1. Marketing Strategy
        • 19.6.6.5.2. Product Strategy
        • 19.6.6.5.3. Channel Strategy
    • 19.6.7. Mylan N.V
      • 19.6.7.1. Overview
      • 19.6.7.2. Product and Disorder Portfolio
      • 19.6.7.3. Production Footprint
      • 19.6.7.4. Sales Footprint
      • 19.6.7.5. Strategy
        • 19.6.7.5.1. Marketing Strategy
        • 19.6.7.5.2. Product Strategy
        • 19.6.7.5.3. Channel Strategy
    • 19.6.8. Fitbit, Inc
      • 19.6.8.1. Overview
      • 19.6.8.2. Product and Disorder Portfolio
      • 19.6.8.3. Production Footprint
      • 19.6.8.4. Sales Footprint
      • 19.6.8.5. Strategy
        • 19.6.8.5.1. Marketing Strategy
        • 19.6.8.5.2. Product Strategy
        • 19.6.8.5.3. Channel Strategy
    • 19.6.9. Garmin Ltd
      • 19.6.9.1. Overview
      • 19.6.9.2. Product and Disorder Portfolio
      • 19.6.9.3. Production Footprint
      • 19.6.9.4. Sales Footprint
      • 19.6.9.5. Strategy
        • 19.6.9.5.1. Marketing Strategy
        • 19.6.9.5.2. Product Strategy
        • 19.6.9.5.3. Channel Strategy
    • 19.6.10. Lucimed S.A.
      • 19.6.10.1. Overview
      • 19.6.10.2. Product and Disorder Portfolio
      • 19.6.10.3. Production Footprint
      • 19.6.10.4. Sales Footprint
      • 19.6.10.5. Strategy
        • 19.6.10.5.1. Marketing Strategy
        • 19.6.10.5.2. Product Strategy
        • 19.6.10.5.3. Channel Strategy
    • 19.6.11. RedMed Inc.
      • 19.6.11.1. Overview
      • 19.6.11.2. Product and Disorder Portfolio
      • 19.6.11.3. Production Footprint
      • 19.6.11.4. Sales Footprint
      • 19.6.11.5. Strategy
        • 19.6.11.5.1. Marketing Strategy
        • 19.6.11.5.2. Product Strategy
        • 19.6.11.5.3. Channel Strategy
    • 19.6.12. Compass Health Brands (Carex Health)
      • 19.6.12.1. Overview
      • 19.6.12.2. Product and Disorder Portfolio
      • 19.6.12.3. Production Footprint
      • 19.6.12.4. Sales Footprint
      • 19.6.12.5. Strategy
        • 19.6.12.5.1. Marketing Strategy
        • 19.6.12.5.2. Product Strategy
        • 19.6.12.5.3. Channel Strategy
    • 19.6.13. Beurer GmbH
      • 19.6.13.1. Overview
      • 19.6.13.2. Product and Disorder Portfolio
      • 19.6.13.3. Production Footprint
      • 19.6.13.4. Sales Footprint
      • 19.6.13.5. Strategy
        • 19.6.13.5.1. Marketing Strategy
        • 19.6.13.5.2. Product Strategy
        • 19.6.13.5.3. Channel Strategy
    • 19.6.14. Samarit Medical AG
      • 19.6.14.1. Overview
      • 19.6.14.2. Product and Disorder Portfolio
      • 19.6.14.3. Production Footprint
      • 19.6.14.4. Sales Footprint
      • 19.6.14.5. Strategy
        • 19.6.14.5.1. Marketing Strategy
        • 19.6.14.5.2. Product Strategy
        • 19.6.14.5.3. Channel Strategy
    • 19.6.15. Lanaform N.V.
      • 19.6.15.1. Overview
      • 19.6.15.2. Product and Disorder Portfolio
      • 19.6.15.3. Production Footprint
      • 19.6.15.4. Sales Footprint
      • 19.6.15.5. Strategy
        • 19.6.15.5.1. Marketing Strategy
        • 19.6.15.5.2. Product Strategy
        • 19.6.15.5.3. Channel Strategy

20. Assumptions and Acronyms Used

21. Research Methodology